Twenty years on: RECIST as a biomarker of response in solid tumours. An EORTC Imaging Group – ESOI joint paper

Fournier, L, de Geus-Oei, L-F, Regge, D , Oprea-Lager, D E, Danastasi, M, Bidaut, Luc, Baeuerle, T, Lopci, E, Cappello, G, Lecouvet, F, Mayerhoefer, M E, Kunz, W G, Verhoeff, J, Caruso, D, Smits, M, Hoffmann, R-T, Gourtsoyianni, S, Beets-Tan, R G H, Neri, E, de Souza, N, Deroose, C M and Caramella, C (2022) Twenty years on: RECIST as a biomarker of response in solid tumours. An EORTC Imaging Group – ESOI joint paper. Frontiers in Oncology . ISSN 2234-943X

Full content URL: https://doi.org/10.3389/fonc.2021.800547

Documents
Twenty years on: RECIST as a biomarker of response in solid tumours. An EORTC Imaging Group – ESOI joint paper
Authors' Accepted Manuscript
[img]
[Download]
[img]
Preview
PDF
hk800547_Manuscript.PDF - Whole Document
Available under License Creative Commons Attribution 4.0 International.

2MB
Item Type:Article
Item Status:Live Archive

Abstract

Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for evaluating efficacy of therapies in patients with solid tumours who are included in clinical trials, and they are widely used and accepted by regulatory agencies. This expert statement discusses the principles underlying RECIST, as well as their reproducibility and limitations.
While the RECIST framework may not be perfect, the scientific bases for the anticancer drugs that have been approved using a RECIST-based surrogate endpoint remain valid. Importantly, changes in measurement have to meet thresholds defined by RECIST for reponse classification within thus partly circumventing the problems of measurement variability. The RECIST framework also applies to clinical patients in individual settings even though the relationship between tumour size changes and outcome from cohort studies is not necessarily translatable to individual cases. As reproducibility of RECIST measurements is impacted by reader experience, choice of target lesions and detection/interpretation of new lesions, it can result in patients changing response categories when measurements are near threshold values or if new lesions are missed or incorrectly interpreted.
There are several situations where RECIST will fail to evaluate treatment-induced changes correctly; knowledge and understanding of these is crucial for correct interpretation. Also, some patterns of response/progression cannot be correctly documented by RECIST, particularly in relation to organ-site (e.g. bone without associated soft-tissue lesion) and treatment type (e.g. focal therapies). These require specialist reader experience and communication with oncologists to determine the actual impact of the therapy and best evaluation strategy. In such situations, alternative imaging markers for tumour response may be used but the sources of variability of individual imaging techniques need to be known and accounted for. Communication between imaging experts and oncologists regarding the level of confidence in a biomarker is essential for the correct interpretation of a biomarker and its application to clinical decision-making. Though measurement automation is desirable and potentially reduces the variability of results, associated technical difficulties must be overcome, and human adjudications may be required.

Keywords:tumour, response, biomarker, imaging, RECIST
Subjects:B Subjects allied to Medicine > B820 Radiology
B Subjects allied to Medicine > B190 Anatomy, Physiology and Pathology not elsewhere classified
A Medicine and Dentistry > A300 Clinical Medicine
G Mathematical and Computer Sciences > G740 Computer Vision
Divisions:College of Science > School of Computer Science
ID Code:48385
Deposited On:28 Feb 2022 09:15

Repository Staff Only: item control page